Lunit SCOPE PD-L1

Lunit SCOPE PD-L1 is an AI-powered software tool designed to assist researchers and pathologists in detecting and classifying PD-L1 biomarker expression across a broad range of cancer types. By analyzing digitized immunohistochemistry (IHC) whole slide images derived from formalin-fixed paraffin embedded (FFPE) tissue, the platform supports consistent, quantitative assessment of PD-L1 status while enhancing overall productivity. It is intended for research use only and is not for use in diagnostic procedures or decisions.

Developed with input from over 150 pathologists worldwide and trained on more than one million cell annotations, Lunit SCOPE PD-L1 delivers validated, reliable results that reduce interpretation discrepancies between readers. The platform is built to empower research and pharmaceutical teams globally with ease of use, powerful analytics, and unmatched processing speeds in digital pathology.

Core Capabilities

• AI-powered PD-L1 detection and classification: Analyzes digitized IHC whole slide images to assist in detecting and classifying PD-L1 biomarker expression, enabling quantitative tissue analysis with precision and efficiency.
• Trusted, validated results: Trained with over one million cell annotations contributed by more than 150 pathologists worldwide, ensuring reliable and reproducible outputs.
• Reduced inter-observer discrepancy: Delivers objective, quantitative results that minimize interpretation differences between readers, supporting greater consistency across studies.
• Broad cancer type coverage: Designed to support PD-L1 IHC expression analysis across a wide range of cancer types.

Clinically Evidenced Performance

• Improved scoring accuracy: Lunit SCOPE PD-L1 enhances scoring accuracy for complex images, including edge or ambiguous samples, as demonstrated in clinical validation studies for immune checkpoint inhibitor response prediction in non-small cell lung cancer (Kim H. et al., JCO Precis Oncol, 2024).
• Enhanced scoring agreement: Proven to deliver objective, reliable analysis results with improved reading consistency and scoring agreement between observers (Choi S. et al., 2022).
• Reduced reading time: Clinical evidence demonstrates that the platform can reduce pathologist reading time by 32%, improving workflow efficiency (Kim S. et al., JCO, 2022).

Workflow and Integration

• Seamless platform interoperability: Integrates directly into leading digital pathology platforms, including Leica Biosystems' Aperio AI Store, Indica Labs' HALO AP®, and Roche navify®.
• Compatibility with scanners and image management systems: Designed to be compatible with a wide range of scanners and image management systems, supporting flexible deployment across research environments.
• Support for CRO and pharma partnerships: Backed by deep expertise and partnerships with numerous contract research organizations (CROs) and digital pathology platform providers, enabling versatile and collaborative research workflows.

Lunit SCOPE PD-L1 is part of a broader suite of AI pathology solutions from Lunit, which also includes tools for HER2 analysis, universal IHC biomarker development, genotype prediction, and tumor microenvironment immune phenotyping. The platform is for research use only and is not intended for use in diagnostic procedures or decisions.